The present invention concerns a glutamate modifying transaminase for use in the treatment of a medical condition selected from the group consisting of brain anoxia, brain ischemia, stroke, perinatal brain damage, traumatic brain injury, bacterial meningitis, subarachnoid haemorhage, migraine, stress, hemorrhagic shock, epilepsy, acute liver failure, glaucoma, HIV, dementia, amyotrophic lateral sclerosis (ALS), spastic conditions, open heart surgery, aneurism surgery, coronary artery bypass grafting and Alzheimers disease.